{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-200159","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.580147+00:00","generated_at":"2026-05-17T07:01:19.688361+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch","bullets":["Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.","Proceeds to advance avexitide commercial readiness, R&D, working capital, and general corporate purposes.","Underwriting led by Leerink Partners and Guggenheim Securities; expected closing September 11, 2025.","Underwriters granted 30-day option to purchase up to 2.625M additional shares at offering price less discounts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-200159","json":"https://secwatch.observer/filing/0001193125-25-200159.json","markdown":"https://secwatch.observer/filing/0001193125-25-200159.md","text":"https://secwatch.observer/filing/0001193125-25-200159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525200159/0001193125-25-200159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525200159/d947193d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:01:19.688361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}